1. Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.
- Author
-
Nahar, Saifun, Huang, Yue, Nagy, Bethany A., Zebala, John A., Maeda, Dean Y., Rudloff, Udo, Oppenheim, Joost J., and Yang, De
- Subjects
PROTEINS ,EXPERIMENTAL design ,FLOW cytometry ,DRUG efficacy ,CATHELICIDINS ,IMMUNIZATION ,IMMUNE checkpoint inhibitors ,ANIMAL experimentation ,ONE-way analysis of variance ,ANTINEOPLASTIC agents ,ORGANELLES ,GENE expression ,RESEARCH funding ,BREAST tumors ,IMMUNOTHERAPY ,DISEASE remission ,ANIMALS ,MICE - Abstract
Simple Summary: There is currently no effective therapy available for triple-negative breast cancer. To look for potentially effective treatment, we used the 4T1 mouse model of triple-negative breast carcinoma to study the therapeutic response of TheraVac (an antitumor therapeutic vaccination regimen) in combination with FSL-1 and/or SX682. The data show that 4T1 tumors can be successfully treated with two TheraVac modifications, with the development of anti-4T1 immune responses in the treated mice. Therefore, these TheraVac modifications have potential to be developed into effective immunotherapies for triple-negative breast cancer. Triple-negative breast carcinoma (TNBC) is one of the most aggressive types of solid-organ cancers. While immune checkpoint blockade (ICB) therapy has significantly improved outcomes in certain types of solid-organ cancers, patients with immunologically cold TNBC are afforded only a modest gain in survival by the addition of ICB to systemic chemotherapy. Thus, it is urgently needed to develop novel effective therapeutic approaches for TNBC. Utilizing the 4T1 murine model of TNBC, we developed a novel combination immunotherapeutic regimen consisting of intratumoral delivery of high-mobility group nucleosome binding protein 1 (HMGN1), TLR2/6 ligand fibroblast-stimulating lipopeptide (FSL-1), TLR7/8 agonist (R848/resiquimod), and CTLA-4 blockade. We also investigated the effect of adding SX682, a small-molecule inhibitor of CXCR1/2 known to reduce MDSC trafficking to tumor microenvironment, to our therapeutic approach. 4T1-bearing mice responded with significant tumor regression and tumor elimination to our therapeutic combination regimen. Mice with complete tumor regressions did not recur and became long-term survivors. Treatment with HMGN1, FSL-1, R848, and anti-CTLA4 antibody increased the number of infiltrating CD4+ and CD8+ effector/memory T cells in both tumors and draining lymph nodes and triggered the generation of 4T1-specific cytotoxic T lymphocytes (CTLs) in the draining lymph nodes. Thus, we developed a potentially curative immunotherapeutic regimen consisting of HMGN1, FSL-1, R848, plus a checkpoint inhibitor for TNBC, which does not rely on the administration of chemotherapy, radiation, or exogenous tumor-associated antigen(s). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF